Detection and Analysis of Clinical Microbial Infections, Second Edition

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Medical Microbiology".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 2693

Special Issue Editor


E-Mail Website
Guest Editor
Laboratorio di Patologia delle Infezioni Associate all’Impianto (Research Unit on Implant Infections), IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy
Interests: implant-associated infections; anti-infective substances and strategies; virulence factors; bacterial biofilm; bacterial molecular epidemiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is a continuation of our previous Special Issue, “Detection and Analysis of Clinical Microbial Infections” (https://www.mdpi.com/si/156117 ).

Microbiological infections and diseases can be caused by bacteria, viruses, parasites, and fungi. This issue has caused worldwide concern and requires the rapid detection and identification of the pathogens responsible for microbial infections. The first crucial and complex phase of the diagnostic process is the definition of the methods for collecting microbiological samples. In fact, depending on the heterogeneous diffusion and probable low number of pathogenic microorganisms, as well as on the chosen diagnostic method that will be used, sampling can be considered a difficult step, especially in chronic infections. The identification methods can be grouped into different clinical–diagnostic categories, namely, methods of isolation and culture with the determination of phenotypic and biochemical characteristics; morphological observation under microscope, particularly used for mixed microbial populations and non-culturable pathogens; antigenic tests, commonly used for their rapidity and simplicity; serological assays, with high specificity and sensitivity; and molecular biology techniques, for a definite microorganism recognition. "-Omics" technologies, in particular genomics (PCR, PFGE, ribotyping, RFLP, RAPD-PCR, DNA sequencing, WGS) and transcriptomics (qPCR, RNA sequencing), but also proteomics (MALDI-TOF MS) and metabolomics (mass spectrometry-based methods), with an improved advancement of their limit of detection, are considered the cornerstones of clinical microbial analysis.

In addition to the demand for a rapid and accurate diagnosis, due to new emerging microbial pathogens, there is a need for the greater standardization of testing and centralized laboratories with the ability to collect and analyze large quantities of samples and perform various identification techniques.

Research articles and systematic reviews are both welcome.

Manuscript topics may include the following:

  • Identification of unculturable pathogens and mixed microbial populations.
  • Sampling, culture, and isolation of the pathogen responsible for infectious diseases.
  • Advantages and limits of clinical microbial identification techniques.
  • New molecular biology techniques for microbial identification.
  • Standardization of techniques and sample data centralization.

Dr. Stefano Ravaioli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microorganisms’ detection and analysis
  • clinical microbiology
  • identification technologies
  • new identification methods
  • heterogeneous dissemination
  • unculturable pathogens
  • mixed microbial populations
  • new emerging pathogens
  • genomics, transcriptomics, proteomics, metabolomics
  • standardization of testing
  • sample data centralization

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

8 pages, 205 KiB  
Communication
Clinical Evaluation of a Rapid Reciprocal-Flow PCR Assay and Real-Time PCR Assay with Quenching Probe for Detection of Mycobacterium tuberculosis Complex
by Kosuke Kosai, Keisuke Matsumoto, Takahisa Ishikawa, Yasuhide Kawamoto, Norihiko Akamatsu, Kenji Ota, Fujiko Mitsumoto-Kaseida, Norihito Kaku, Hiroo Hasegawa, Koichi Izumikawa, Hiroshi Mukae and Katsunori Yanagihara
Microorganisms 2025, 13(1), 201; https://doi.org/10.3390/microorganisms13010201 - 17 Jan 2025
Viewed by 452
Abstract
This study investigated the diagnostic efficiencies of two assays for the detection of Mycobacterium tuberculosis complex: (1) the reciprocal-flow real-time polymerase chain reaction (PCR)-based GeneSoC assay and (2) the real-time PCR based GENECUBE MTB assay with quenching probe. These assays were performed for [...] Read more.
This study investigated the diagnostic efficiencies of two assays for the detection of Mycobacterium tuberculosis complex: (1) the reciprocal-flow real-time polymerase chain reaction (PCR)-based GeneSoC assay and (2) the real-time PCR based GENECUBE MTB assay with quenching probe. These assays were performed for stored clinical samples and results were compared with the confirmed results based on culture and COBAS TaqMan MTB assay. A total of 53 samples (20 confirmed positives and 33 confirmed negatives) were included in the performance analysis. The GeneSoC assay showed concordance in all 53 samples, regardless of specimen type, while the GENECUBE MTB assay showed concordance in 19 of the 20 confirmed positive samples and all 33 confirmed negative samples. The overall agreement was 100.0% for the GeneSoC assay and 98.1% for the GENECUBE MTB assay. Positive and negative percent agreements were 100.0% each for the GeneSoC assay and 95.0% and 100.0%, respectively, for the GENECUBE MTB assay. Both the GeneSoC and GENECUBE MTB assays exhibited excellent performance in detecting M. tuberculosis complex. The GeneSoC assay is useful for independent assays of individual samples, whereas the GENECUBE MTB assay is suitable for batch assays of multiple samples. Full article
14 pages, 2035 KiB  
Article
Evaluation of a Commercial Multiplex Real-Time PCR with Melting Curve Analysis for the Detection of Mycobacterium tuberculosis Complex and Five Nontuberculous Mycobacterial Species
by Keun Ju Kim, Yunhee Chang, Seung Gyu Yun, Myung-Hyun Nam and Yunjung Cho
Microorganisms 2025, 13(1), 26; https://doi.org/10.3390/microorganisms13010026 - 26 Dec 2024
Viewed by 904
Abstract
Background: Accurate and timely diagnosis of mycobacterial infections, including Mycobacterium tuberculosis complex (MTBC) and nontuberculous mycobacteria (NTM), is crucial for effective disease management. Methods: This study evaluated the performance of the NeoPlex TB/NTM-5 Detection Kit (NeoPlex assay, Seongnam, Republic of Korea), a multiplex [...] Read more.
Background: Accurate and timely diagnosis of mycobacterial infections, including Mycobacterium tuberculosis complex (MTBC) and nontuberculous mycobacteria (NTM), is crucial for effective disease management. Methods: This study evaluated the performance of the NeoPlex TB/NTM-5 Detection Kit (NeoPlex assay, Seongnam, Republic of Korea), a multiplex real-time PCR assay that incorporates melting curve analysis, compared with the line-probe assay (LPA). The NeoPlex assay could simultaneously detect and differentiate MTBC from five other NTM species: Mycobacterium intracellulare, Mycobacterium avium, Mycobacterium kansasii, Mycobacterium abscessus, and Mycobacterium massiliense. A total of 91 acid-fast bacillus culture-positive samples, comprising 36 MTBC and 55 NTM isolates, were collected from the Korea University Anam Hospital. Results: The NeoPlex assay successfully detected nucleic acids in 87 of the 91 isolates (95.6%). Notably, it identified additional mycobacterial nucleic acids not detected by the LPA in eight isolates. These findings were confirmed via DNA sequencing. The assay had 100% sensitivity and specificity for M. intracellulare, M. abscessus, M. massilense, NTM, and MTBC, whereas it had 100% specificity and sensitivity of 90.9% and 75.0% for M. avium and M. kansasii, respectively. Conclusions: These results highlight the potential of the NeoPlex assay to enhance rapid and accurate diagnosis of mycobacterial infections, particularly in settings in which prompt treatment initiation is essential. Full article
Show Figures

Figure 1

10 pages, 561 KiB  
Article
Characterization of Unusual Serogroups of Neisseria meningitidis
by Samy Taha, Giulia Fantoni, Eva Hong, Aude Terrade, Oumar Doucoure, Ala-Eddine Deghmane and Muhamed-Kheir Taha
Microorganisms 2024, 12(12), 2528; https://doi.org/10.3390/microorganisms12122528 - 7 Dec 2024
Viewed by 853
Abstract
Most cases of invasive meningococcal disease (IMD) in Europe are caused by isolates of the Neisseria meningitidis serogroups B, C, W, and Y. We aimed to explore cases caused by other unusual serogroups. We retrospectively screened IMD cases in the databases of the [...] Read more.
Most cases of invasive meningococcal disease (IMD) in Europe are caused by isolates of the Neisseria meningitidis serogroups B, C, W, and Y. We aimed to explore cases caused by other unusual serogroups. We retrospectively screened IMD cases in the databases of the National Reference Center for Meningococci and Haemophilus influnezae in France between 2014 and 2023. Age, sex, serogroups, and genetic lineage distributions were analyzed. We also measured complement deposition on the bacterial surface and tested coverage by vaccines against serogroup B. Cases due to isolates of serogroups other than B, C, W, and Y represented 1.6% of all 3610 IMD cases during the study period with 59 cases and a median age of 21.5 years of age. The corresponding isolates were non-groupable (26 cases), serogroup X (21 cases), serogroup E (11 cases), and one isolate belonged to serogroup Z. Only a low proportion (7.4%) belonged to the hyperinvasive genetic lineages. Isolates of serogroup E bound a significantly higher amount of complement on their surface and were mainly detected in patients with terminal complement pathway deficiencies. Isolates of these unusual serogroups were shown to be covered by vaccines licensed against meningococci B. Surveillance of these isolates needs to be enhanced. Full article
Show Figures

Figure 1

Back to TopTop